Patent · US Active

Use of EEF1A as biomarker and a method of screening MetAP2 inhibitors

US9151743B2 · kind B2 · utility

0Cited by

0References

5Claims

0Family size

Assignee

Merck Patent GmbH · DE

Inventors

Roland Kellner · Heppenheim, DE
Frank Zenke · Darmstadt, DE
Joerg Bomke · Heidelberg, DE

Key dates

Filing date	Oct 5, 2009
Grant date	Oct 6, 2015
Priority date	—
Expiry date	Sep 24, 2030

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The invention relates to a method for screening compounds, which inhibit MetAP2 activity, by providing a cellular system or a sample thereof being capable of expressing MetAP2 and/or EEF1A, incubating at least a portion of the system with compounds to be screened, and detecting MetAP2 inhibition by determining EEF1A with N-terminal methionine residue (MetEEF1A). Another object of the invention concerns a method for monitoring physiological and/or pathological conditions, which are caused, mediated and/or propagated by MetAP2 activity, by administering an effective amount of at least a single compound to a mammal in need of such treatment and determining MetEEF1A in a biological sample withdrawn from the mammal. The invention also relates to the use of EEF1A as biomarker.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.